Can an Aragonite Scaffold Help Repair Knee Cartilage Lesions?

If you have been told you have a cartilage defect in the knee, the difficult question is usually not just “can it be fixed?” It is whether a procedure is real, durable, and worth the disruption of surgery and travel. This five-year trial is useful because it compares a newer aragonite-based scaffold with familiar surgical options, but it still needs to be read carefully ¹.

What question did the researchers ask?

The researchers wanted to know whether an aragonite-based osteochondral implant could do better than surgical standard of care for painful cartilage or cartilage-and-bone lesions in the knee. The comparison group received arthroscopic debridement or microfracture, two established approaches that aim to clean or stimulate repair in damaged cartilage areas.

This was not a stem cell injection study. It was a surgical trial of a scaffold implant placed into selected knee defects. Adults aged 21 to 75 were enrolled if they had up to three cartilage defects on the femoral condyles and/or trochlea, with a total treatable area of 1 to 7 cm2 and a bony defect depth of 8 mm or less. Importantly, the study allowed people with no osteoarthritis through to mild or moderate osteoarthritis, defined by Kellgren-Lawrence grades 0 to 3.

That matters because many cartilage repair trials exclude patients once early arthritis appears. In real clinics, patients rarely arrive with a perfectly isolated defect and a completely normal joint. This trial tried to study a group closer to what surgeons may actually see, while still using strict entry criteria ¹.

For background on the broader condition, our guide to knee osteoarthritis and treatment choices explains why cartilage symptoms, bone changes, alignment, inflammation, and load all need to be considered together.

What did the five-year results show?

The headline result was that patient-reported knee function improved more in the scaffold group than in the surgical-standard-care group at five years. In the abstract, the final overall KOOS result was 81.0 in the implant group versus 59.1 in the standard-care group, a 22.6-point difference.

KOOS stands for Knee injury and Osteoarthritis Outcome Score. It is a patient questionnaire, not a microscope view of new cartilage. A higher score generally means the person reports better pain, symptoms, daily function, sports or recreation ability, and knee-related quality of life.

Another useful figure is the responder rate. The study defined response as at least a 30-point improvement in overall KOOS. By that definition, 74.7% of patients in the implant group were responders compared with 29.6% in the standard-care group. Treatment failure, defined as the need for any secondary treatment, was also lower in the implant group than in the standard-care group in the abstract.

How strong is this evidence?

For a cartilage repair study, this is relatively strong evidence. It was a multicenter randomized controlled trial, described as Level 1 evidence, with 26 centers across 8 countries. The trial included 251 treated patients: 167 received the aragonite-based implant and 84 received standard surgical care. Follow-up compliance at five years was also fairly high, at 88.4% in the implant group and 83.1% in the standard-care group.

Those strengths do not make the result universal. The patients were carefully selected. Their defects had defined locations, sizes, and bone-depth limits. People with more advanced arthritis were not the main population studied, and a knee with major malalignment, severe bone-on-bone change, inflammatory arthritis, or multiple drivers of pain may behave very differently.

The main outcome was patient-reported KOOS. That is important because symptoms and function are what patients live with, but it does not prove that the joint became normal cartilage again. The abstract also does not tell us every practical detail a patient might need, such as rehabilitation burden, imaging durability by subgroup, surgeon learning curve, cost, or how results varied between centers.

Another limitation is that the paper is not open access, so many readers will only see the abstract unless they have journal access. From the abstract alone, the trial appears encouraging and well designed, but a clinical decision should be made from the full paper, imaging, examination, and surgical judgement, not from the headline numbers alone.

What could this mean if you are considering treatment?

The study suggests that, for selected patients with focal cartilage or osteochondral knee lesions, an aragonite-based scaffold may offer better five-year symptom and function outcomes than microfracture or debridement. That is meaningful, especially because the study included some patients with mild to moderate osteoarthritis, a group often left out of cartilage trials.

It does not mean the implant is right for every sore knee. It does not prove that advanced osteoarthritis can be reversed. It also does not remove the usual questions around surgery: diagnosis, lesion location, knee alignment, meniscus status, body weight, activity goals, rehabilitation time, complication risk, and what happens if the procedure fails.

For patients comparing options, this paper is best seen as a reason to ask more precise questions. Is my pain coming from one treatable cartilage defect, or from the whole joint? Is my osteoarthritis mild enough that a repair procedure still makes sense? What would standard care be in my case, and what outcome would count as a realistic success?

If you are trying to understand how this fits beside biologic and regenerative approaches, our article on stem cells for knee osteoarthritis may help separate surgical scaffold repair from injection-based therapies.

What we see at the clinic

In our Pattaya clinic, people often ask whether a scan showing “cartilage loss” automatically means they need a regenerative treatment or a joint replacement. Our physicians spend much of the first conversation separating focal cartilage defects from more general osteoarthritis, because the same MRI wording can mean very different things for different knees.

Common questions

Is this the same as a stem cell treatment? No. This paper studied a surgically placed aragonite-based scaffold, not a stem cell injection. Some patients researching regenerative medicine group these treatments together, but they are different procedures with different risks, recovery demands, and evidence.

Does the study prove cartilage was fully restored? No. The key abstract results are based on patient-reported knee scores and treatment failure, not a guarantee of normal cartilage regrowth. A better KOOS score can be clinically important, but it should not be oversold as a rebuilt knee.

Would this help severe knee osteoarthritis? The study included patients up to Kellgren-Lawrence grade 3, but it was still a selected cartilage-lesion trial. Severe, widespread, bone-on-bone arthritis may need a very different discussion, including non-surgical care, unloading strategies, or joint replacement assessment.

Key takeaway

This five-year randomized trial is a useful, cautiously encouraging study for selected cartilage and osteochondral knee lesions. The aragonite scaffold group reported better knee scores than standard surgical care, but the evidence does not mean every painful or arthritic knee can be repaired. The safest expectation is modest: this may be a relevant surgical option to discuss if your knee problem is focal, well imaged, and judged suitable by an experienced physician.